Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.
Martín M, Stecklein SR, Gluz O, Villacampa G, Monte-Millán M, Nitz U, Cobo S, Christgen M, Brasó-Maristany F, Álvarez EL, Echavarría I, Conte B, Kuemmel S, Bueno-Muiño C, Jerez Y, Kates R, Cebollero M, Kolberg-Liedtke C, Bueno O, García-Saenz JÁ, Moreno F, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstleins R, Graeser M, Zu Eulenburg C, Kreipe HH, Gómez H, Massarrah T, Herrero B, Paré L, Bohn U, López-Tarruella S, Vivancos A, Sanfeliu E, Parker JS, Perou CM, Villagrasa P, Prat A, Sharma P, Harbeck N. Martín M, et al. Among authors: herrero b. Ann Oncol. 2024 Oct 16:S0923-7534(24)04061-4. doi: 10.1016/j.annonc.2024.10.012. Online ahead of print. Ann Oncol. 2024. PMID: 39419289 Free article.
Safety and outcome of children, adolescents and young adults participating in phase I/II clinical oncology trials: a 9-year center experience.
Pujol Manresa A, Buendía López S, Andión M, Herrero B, Lassaletta Á, Ramirez M, Ruano D, Hernández-Marqués C, Varo A, de Rojas T, Cortés Hernández M, Verdú-Amorós J, Martín Prado S, Artigas A, Redondo E, Ruiz Pato J, Herreros López P, Sevilla J, Madero L, Moreno L, Bautista Sirvent F, Rubio-San-Simón A. Pujol Manresa A, et al. Among authors: herrero b. Front Pediatr. 2024 Sep 4;12:1423484. doi: 10.3389/fped.2024.1423484. eCollection 2024. Front Pediatr. 2024. PMID: 39318620 Free PMC article.
Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients.
Mingot-Castellano ME, Reguera-Ortega JL, Zafra Torres D, Hernani R, Lopez-Godino O, Guerreiro M, Herrero B, López-Corral L, Luna A, Gonzalez-Pinedo L, Chinea-Rodriguez A, Africa-Martín A, Bailen R, Martinez-Cibrian N, Balsalobre P, Filaferro S, Alonso-Saladrigues A, Barba P, Perez-Martinez A, Calbacho M, Perez-Simón JA, Sánchez-Pina JM, On Behalf Of The Spanish Group Of Hematopoietic Transplant And Cell Therapy Geth-Tc. Mingot-Castellano ME, et al. Among authors: herrero b. J Clin Med. 2024 Aug 28;13(17):5117. doi: 10.3390/jcm13175117. J Clin Med. 2024. PMID: 39274330 Free PMC article.
Non-immune hydrops fetalis is associated with bi-allelic pathogenic variants in the MYB Binding Protein 1a (MYBBP1A) gene.
Tenorio-Castano J, Mansilla Aparicio E, García Santiago FA, Klotz CM, Regojo RM, Anguita E, Ryan E, Juusola J, Herrero B, Arias P, Parra A, Pascual P, Gallego N, Cazalla M, Rodriguez-González R, Antolín E, Nevado J, Ruiz-Perez VL, Lapunzina P. Tenorio-Castano J, et al. Among authors: herrero b. Clin Genet. 2024 Dec;106(6):713-720. doi: 10.1111/cge.14601. Epub 2024 Aug 27. Clin Genet. 2024. PMID: 39191491
Prenatal Management and Perinatal Outcome in a Large Series of Hydrops Fetalis.
Sebastián de Lucas LM, Ordás Álvarez P, de Castro Marzo L, Illescas Molina T, Herrero B, Bartha JL, Antolín E. Sebastián de Lucas LM, et al. Among authors: herrero b. Fetal Diagn Ther. 2024;51(4):335-342. doi: 10.1159/000538857. Epub 2024 Apr 20. Fetal Diagn Ther. 2024. PMID: 38643756
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.
Juan-Ribelles A, Bautista F, Cañete A, Rubio-San-Simón A, Alonso-Saladrigues A, Hladun R, Rives S, Dapena JL, Fernández JM, Lassaletta Á, Cruz O, Ramírez-Villar G, Fuster JL, de Heredia CD, García-Ariza M, Quiroga E, Del Mar Andrés M, Verdú-Amorós J, Molinés A, Herrero B, López M, Márquez C, Toboso M, Lendínez F, Sirvent JG, Tallón M, Rodríguez G, Acha T, Moreno L, Fernández-Teijeiro A; Sociedad Española de Hematología y Oncología Pediátrica (SEHOP). Juan-Ribelles A, et al. Among authors: herrero b. Clin Transl Oncol. 2024 Sep;26(9):2351-2359. doi: 10.1007/s12094-024-03445-0. Epub 2024 Apr 10. Clin Transl Oncol. 2024. PMID: 38600340 Free PMC article.
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S, Pérez-Simón JA. Molinos-Quintana Á, et al. Among authors: herrero b. Front Immunol. 2024 Feb 7;15:1373852. doi: 10.3389/fimmu.2024.1373852. eCollection 2024. Front Immunol. 2024. PMID: 38384474 Free PMC article.
91 results